医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson’s Disease

2016年03月24日 AM09:16
このエントリーをはてなブックマークに追加


 

SYDNEY & AUCKLAND, New Zealand

Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015, and the Northern A Health and Disability Ethics Committee gave its approval on 3 February 2016. The initiation meeting with all those involved in the clinical trial has been held and patient recruitment is under way.

The Phase IIb trial follows the successful Phase I/IIa trial, which met the primary endpoint of safety and showed clinically and statistically significant efficacy data in patients with Parkinson’s disease one year after NTCELL treatment.

The Phase IIb trial aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group.

If the trial is successful the company will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.

For further information: www.lctglobal.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160323006637/en/

CONTACT

At the Company:
Living Cell Technologies Limited
Ken
Taylor, +64 9 276 2690
Chief Executive
ktaylor@lctglobal.com
Mobile:
+64 21 796 000
or
Media Contact:
Botica Butler
Raudon Partners
Rachael Joel, +64 9 303 3862
rachaelj@botica.co.nz
Mobile:
+64 21 403 504

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 仁和集团与APR应用制药研究公司公布协议在中国市场销售治疗偏头痛创新药
  • 武田连续第二年入选全球可持续发展最佳企业百强榜单
  • InFo 124M – 瑞士生产的用于白内障手术的延伸焦深人工晶体
  • 2017 Taiwan WHO Simulation Kicks off at NCKU with 240 Medical Students Sharing
  • 武田薬品: ARIAD社の発行済み全株式に対する現金による公開買付けの開始について